IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense (R) in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines ...
BIRMINGHAM, Ala. — The University of Alabama at Birmingham (UAB) Medicine is now offering cryoablation, a minimally invasive treatment option for breast cancer patients. This innovative procedure, ...
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...
MRI-guided cryoablation debuts in Sydney, offering precise, minimally invasive tumour treatment.
The FDA granted marketing authorization for the ProSense Cryoablation System for small, early-stage breast cancer in older women not suitable for surgery, maker IceCure announced. A minimally invasive ...
Robot-assisted CT-guided cryoablation shows feasibility, safety, and accuracy in complex cases of pulmonary metastases, a prospective study reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results